Biotech Values

[dav1234]

FDA review: Merck's Vorapaxar should be authorized
The FDA says in a preliminary review that Merck's (MRK +0.4%) Vorapaxar drug for preventing drug clots should be approved following "robustly positive" clinical trial results.The recommendation comes two days before a meeting of external FDA advisers to discuss the treatment.Vorapaxar, which Merck plans to sell under the brand name Zontivity, is designed to prevent heart-related deaths, heart attacks and strokes in patients who have recently suffered a heart attack but not a stroke